Jianxin Superconductor's scientific and technological innovation board IPO has been "accepted", mainly engaged in the research and development and sales of core components of medical magnetic resonance imaging equipment.

On May 9th, Ningbo Jiangxin Superconductor Technology Co., Ltd. (referred to as "Jiangxin Superconductor") had its IPO application status for the Shanghai Stock Exchange Science and Technology Innovation Board listed as "accepted". GF SEC is its sponsoring institution, and the company plans to raise 865 million yuan. The prospectus shows that Jiangxin Superconductor is mainly engaged in the research, development, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, with its main products including superconducting magnets, permanent magnets, and gradient coils, accounting for about 50% of the cost of MRI equipment core components. In the superconducting field, the company has developed a rich product portfolio including 1.5T zero boil-off superconducting magnets, 1.5T helium-free superconducting magnets, 3.0T zero boil-off superconducting magnets, and open zero boil-off superconducting magnets, making it the leading independent supplier of superconducting magnets in the global MRI industry. In the permanent magnet field, the company uses high-performance magnetic materials and efficient magnetic circuit designs, and introduces design technologies such as low eddy current and high openness to provide customers with a series of high-quality permanent magnets. It is currently the world's largest supplier of permanent magnets for MRI equipment. Permanent magnet MRI equipment is characterized by high economic efficiency, high examination comfort, strong design flexibility, low maintenance requirements, and low energy consumption, making it easy to popularize in grassroots medical systems and having advantages in interventional treatment and professional applications. During the reporting period, the proportion of revenue from superconducting products has been on the rise. By the end of the 2024 fiscal year, superconducting products accounted for approximately 66% of revenue, while permanent magnet products accounted for approximately 34%. According to data from Yochi Consultancy, based on installed capacity, the top five global superconducting magnet manufacturers in 2024 were Siemens Healthineers, GE Healthcare, Philips Healthcare, Shanghai United Imaging Healthcare, and the company. The company's global market share is approximately 4.2%, ranking fifth globally and second among domestic companies after Shanghai United Imaging Healthcare. As a core component supplier for MRI, the company has established close cooperation with well-known MRI equipment manufacturers at home and abroad such as Japan's Fujifilm Group, GE Healthcare in the United States, Italy's Bracco Imaging, Beijing Wandong Medical Technology, Shenzhen Anke, Shanghai United Imaging Healthcare, and Fukuda Medical, and has promoted the innovation of the MRI equipment overseas supply chain model through the layout of overseas subsidiaries and the transportation process of liquid helium to maintain patent technology. Over 50% of the company's products corresponding to MRI equipment are sold to Japan, Europe, America, and other emerging overseas markets. The funds raised in this issuance, after deducting issuance expenses, will be invested in the following projects: Financially, in the 2022, 2023, and 2024 fiscal years, Jiangxin Superconductor achieved revenues of approximately 359 million yuan, 451 million yuan, and 425 million yuan, respectively. During the same period, net profits were approximately 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan, respectively.